Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with renal impairment

Riociguat is the first oral, soluble guanylate cyclase stimulator under review for the treatment of pulmonary hypertension (PH), a progressive, ultimately fatal disease [1–7]. This pooled analysis of two studies evaluated the pharmacokinetics of riociguat and its metabolite M1 (BAY 60-4552) in individuals with and without renal impairment. The safety and tolerability of riociguat were also assessed.

Two non-randomized, non-blinded, observational studies with group stratification were conducted in a single centre in Germany, following Good Clinical Practice and relevant industry guidelines [8, 9]. Participants were assigned to one of four renal function groups according to their creatinine clearance (CL_CR): group 1, CL_CR > 80 mL/min; group 2, CL_CR 50–80 mL/min; group 3, CL_CR 30–49 mL/min; group 4, CL_CR < 30 mL/min. In the first study, individuals in group 4 received riociguat 0.5 mg; all other participants in both studies received riociguat 1 mg (single tablet doses). Pharmacokinetic parameters were assessed using dense sampling.

Sixty-three participants (40 men and 23 women; mean age, 61.3 years [range, 36–78 years]) completed the study and were eligible for pharmacokinetic analysis. Riociguat was rapidly absorbed; median time to reach maximum concentration in plasma (t_max) (C_max) was 1 hour in all four groups. Mean half-life of total riociguat was longer in groups 2–4 (9.5–11.4 hours) than in group 1 (6.2 hours) (Table 1), and renal clearance of riociguat decreased with decreasing renal function. Mean exposure to total riociguat (area under the concentration–time curve divided by dose per kilogram of body weight [AUC_norm]) was 42.7–104.3% higher in groups 2–4 than in group 1 (Table 1, Figure 1). However, exposure was highly variable in groups 2–4 and the exposure ranges in all groups overlapped (Figure 1). Exposure to riociguat did not increase strictly in parallel with decreasing CL_CR. Results for unbound riociguat and M1 were similar to those for total riociguat and M1. No serious or severe adverse events were reported. Headache was the most common drug-related adverse event. No changes in safety or tolerability were detected with decreasing CL_CR. Riociguat C_max and AUC ranges in patients with renal impairment overlapped those previously observed in healthy volunteers and patients with PH [2, 3].

Box-and-whisker plot of riociguat AUC_norm (kg·h/L) after a single oral dose of riociguat. In the first study, individuals with severe renal impairment (group 4) received riociguat 0.5 mg; all other participants in both studies received riociguat 1 mg . Box, 25–75th percentile; vertical line, 10th–90th percentile; horizontal line, median; more extreme values are plotted as points; individuals eligible for pharmacokinetic analysis, n = 63; AUC_norm, area under the plasma concentration–time curve from time 0 to infinity divided by dose per kilogram of body weight for total riociguat.

Full size image

Exposure to riociguat was higher in individuals with renal impairment (CL_CR 15–80 mL/min) than in controls; particular care should be exercised during individual dose titration in patients with renal impairment.

The studies were funded by Bayer Pharma AG, Wuppertal, Germany, and performed by Atef Halabi, Clinical Trial Director, CRS Clinical Research Services Kiel GmbH, Lornsenstrasse 7, 24105 Kiel, Germany.

Affiliations

1. Clinical Pharmacology, Bayer Pharma AG, Pharma Research Centre, Wuppertal, Germany

   • Reiner Frey
   • , Corina Becker
   • , Anja Schmidt
   • , Georg Wensing
   •  & Wolfgang Mueck

2. Global Biostatistics, Bayer Pharma AG, Pharma Research Centre, Wuppertal, Germany

   • Sigrun Unger

Corresponding author

Correspondence to Reiner Frey.

Reprints and Permissions